L-AP4 is a selective group III metabotropic glutamate receptor agonist..

Lapatinib

Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.

Lapatinib ditosylate(GW-572016 ditosylate) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.

Laquinimod (ABR-215062) is a potent immunomodulator.

L-Arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.

LAS195319 (LAS-195319) is a potent, selective, inhaled PI3Kδ inhibitor with IC50 of 0.5 nM, weakly inhibits PI3Kβ and γ (>20-fold), no activity against PI3Kα.

Lasmiditan (COL-144; LY573144) is a high-affinity, highly selective 5-HT1F receptor agonist(Ki=2.1 nM), compared with Ki of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively.

Lasofoxifene Tartrate is a non-steroidal selective estrogen receptor modulator (SERM).

LASV inhibitor 3.3 (LAMP1 inhibitor 3.3) is a specific inhibitor of Lassa fever virus (LASV, IC50=1.8 uM), inhibits LASV GP-mediated infection and cross-links to the LASV receptor, LAMP1, in cells; does not inhibits the GP-mediated infection of LCMV, LuJo

Latanoprost is a prodrug (isopropyl ester) of 17-phenyl-13,14-dihydro prostaglandin F2α.

Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis.

LAU159 is a novelα6β3γ2 GABAA receptor inhibitor.

Lauric Acid is a saturated medium-chain fatty acid with a 12-carbon backbone. Lauric acid is found naturally in various plant and animal fats and oils, and is a major component of coconut oil and palm kernel oil.

Lavendustin A is a selective inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase (IC50 = 11 nM) that was first isolated from a Streptomyces culture filtrate.

Lavendustin B is a Tyrosine Kinase Inhibitor amd an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF/p75).

Lazabemide(Ro 19-6327/000) is selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively).

Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations

LB-100 is a small-molecular protein phosphatase 2A(PP2A)inhibitor with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.

LB-102 (LB-1.2, LB 102) is a a selective dopamine D2/3/5-HT7 inhibitor.

LB42908 is a highly potent, selective, orally active inhibitor of Ras farnesyltransferase (FTase) with IC50 of 0.9 nM against H-Ras and 2.4 nM against K-Ras..

LBL1 (Lamin A inhibitor LBL1) is a novel pyrroloquinazoline compound with significant anticancer activity, targets nuclear lamins and binds to the coiled-coil domain of lamin A (Kd=5.11 uM).

LC-1028 (LC1028) is a novel potent selective, covalent and irreversible inhibitor of p97 (valosin-containing protein), remains essentially irreversible ac tivity against p97 mutant C522A..

LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk.

LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk.

LCH 7749944 (GNF-PF-2356) is a novel and potent PAK4 with IC50 of 14.93 uM, shows weak activity against other PAK family members.

Lck Inhibitor is a new class of compounds that are potent inhibitors of Lck with an IC50 value of 7 nM. IC50 Value: 7 nM [1] Target: Lck in vitro: Lck Inhibitor (compound 25) exhibited good potency in the T-cell receptor-induced IL-2 secretion assay (I

LCL161 is an oral small molecule antagonist of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies.

LCL521 is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase).

LCS-1 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.5 uM.

LCS-1.28 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.05-1.6 uM.

LCS-1.34 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.1 uM.

LCZ696 is a first-in-class dual inhibitor of the angiotensin II receptor(AT II receptor) and neprilysin; a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio).

LDC000067(LDC-067) is a highly specific CDK9 inhibitor with IC50 of 32.7 nM for CDK9/cyclin T1; displays 55/125/210/ >227/ >227-fold selectivity for CDK9 versus CDK2/1/4/6/7.

LDC1267 is a highly selective TAM(Tyro3, Axl and Mer) kinase inhibitor with IC50 of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively.

LDC4297 is a novel CDK7 inhibitor.

LDD1937 is a novel potent FLT3 inhibitor with IC50 of 3 nM, displays >170-fold selectivity over JAK2/3, c-MET, IRAK-4.

LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3.

LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3.

LDHA-IN-104 is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50 of 0.87 uM, less potent for LDHB (IC50=6.9 uM).

LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.

LDK378 is a highly selective ALK inhibitor with IC50 of 2 nM

LDN 91946 is a selective, uncompetitive ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor with Ki of 2.8 uM, exhibits no activity against other cysteine hydrolase (UCH-L3, TGase 2, papain and caspase-3)..

LDN-109657 is a novel SMN2 modulator that increase SMN protein levels in 3813 fibroblasts by twofold at 370 nM..

LDN-192960 is a potent and selective inhibitor of haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase). IC50 = 0.010 µm

LDN193189 HCl is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.

LDN193189 is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively.

LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors.

LDN-212320(OSU-0212320) is a glutamate transporter EAAT2 activator; enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.

LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively.

LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM; > 100 fold selectivity for ALK5; also inhibits BMP6(IC50=100 nM).

LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3.

LDN-75654 is a novel potent SMN2 modulator (EC50=1.8 uM.

LDN-76070 is a novel potent SMN2 modulator (EC50=8.3 uM.

LED209 is a potent QseC inhibitor that blocks both norepinephrine- and epinephrine-triggered QseC-dependent virulence gene expression at 5 pM in vitro.

Ledipasvir(GS5885) is an inhibitor of the hepatitis C virus NS5A protein. Ledipasvir is an experimental drug for the treatment of hepatitis C.

LEE011 Hcl is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.

LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.

LEE011 succinate is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.

Lefamulin acetate is a pleuromutilin antibiotic that is being developed by Nabriva Therapeutics for the treatment of acute bacterial skin and skin-structure infections.

Lefamulin is a semi-synthetic compound that inhibits the synthesis of bacterial protein, which is required for bacteria to grow.

Leflunomide

LEI-105 is a potent, highly selective, and reversible dual DAGL-α/DAGL-β inhibitor with pIC50 pf 7.5/7.4 respectively.

LEI110 (LEI－110) is a potent Phospholipase A2 group XVI (PLA2G16) inhibitor with Ki of 20 nM, also has activity on HRASLS2, RARRES3 and iNAT (pIC50=6.8-7.6).

LEM-14 is a specific inhibitor of histone lysine methyltransferase NSD2 (MMSET/WHSC1) with in vitro IC50 of 132 uM, and that is inactive against the closely related NSD1 and NSD3..

LEM-14-1189 is a LEM-14 derivative that differentially inhibits the NSDs with in vitro IC50 of 418 μM (NSD1), IC50 of 111 μM (NSD2) and IC50 of 60 μM (NSD3)..

Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia.

Lenalidomide is a thalidomide analog known to display TNF-α secretion inhibition and possesses immunomodulatory properties.

Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor currently in phase II/III clinical trials for the treatment of immunodeficiency disorders.

Leonurine hydrochloride is an alkaloid isolated from Herba leonuri, with anti-oxidative and anti-inflammatory.

Leonurine, a natural alkaloid extracted from Herba leonuri, has been proved to have anti-inflammatory effect.

LEQ 506 (NPV-LEQ 506) is a second-generation inhibitor of Smoothened (Smo) with IC50 of 2 nM and 4 nM for human and mouse Smo, respectively.

Lercanidipine hydrochloride is a calcium channel blocker of the dihydropyridine class.

Lercanidipine is a calcium channel blocker of the dihydropyridine class.

Lersivirine (UK-453061) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for the treatment of HIV-1 infection.

Lesinurad sodium (RDEA594 sodium) is an once-daily inhibitor of URAT1; URAT1 is a transporter in the kidney that regulates uric acid excretion from the body.

Lesinurad(RDEA594), once-daily inhibitor of URAT1, is a transporter in the kidney that regulates uric acid excretion from the body.

Lesogaberan (AZD-3355) is a potent, selective, peripherally acting GABAB receptor agonist with Ki of 5 nM and EC50 of 8.6 nM, 274-fold selectivity over GABAA (Ki=1.4 uM).

Lestaurtinib (KT-5555, CEP-701) is a potent, orally active JAK2, FLT3 and TrkA inhibitor with IC50 of 0.9 nM, 3 nM and < 25 nM, respectively.

Letaxaban (TAK-442, TAK442) is a potent, selective and direct factor Xa (FXa) inhibitor with Ki of 1.8 nM for hFXa, >440-fold selectivity than thrombin and negligible effects on trypsin, plasmin, and tPA.

Leteprinim (Neotrofin, AIT-082) is a hypoxanthine derivative drug with neuroprotective and nootropic effects.

Lethal toxin inhibitor DN1 is a small molecule that reduces the cytotoxicity of anthrax lethal toxin (LT) an inhibitor of LT-induced pyroptosis, acts as an antagonist of GPCR receptors type-1 angiotensin II receptor (AGTR1) and apelin receptor (APLNR) wit

Letrozole(CGS-20267) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant.

Leucettamine B is a potent inhibitor of CLK1 (IC50=15 nM), Dyrk1A (IC50=40 nM), and Dyrk2 (IC50=35 nM) and a moderate inhibitor of CLK3 (IC50=4.5 uM)..

Leucovorin Calcium is a reduced folic acid.

Leukadherin-1 is a specific agonist of CR3 and the leukocyte surface integrin CD11b/CD18.

Leupeptin hemisulfate is a reversible, competitive serine/cysteine protease inhibitor, which has been shown to inhibit cathepsins B, H, L, and S, calpain, and trypsin. Leupeptin hemisulfate is an orally active, antioxidant and anti-inflammatory agent.

Leuprolide acetate (Leuprorelin) is a GnRH analog; leuprolide acetate acts as an agonist at pituitary GnRH receptors.

Leuprorelin (Leuprolide) is a GnRH analog and agonist of GnRH receptor, interrupts the normal pulsatile stimulation and desensitizing of the GnRH receptors..

Levamisole HCl(Ergamisol)

Levetiracetam

Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker), used to lower the pressure in the eye in treating conditions such as glaucoma.

Levobupivacaine HCL

Levodropropizine is a histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive drug.

Levofloxacin (Levaquin)

Levofloxacin is a broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity.

Levonorgestrel(Levonelle)

Levosimendan

Levosulpiride is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class.

Lexacalcitol

LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 with an IC50 less than 2 μM.

LGB-321 (LGB321) is a potent and specific pan-Pim inhibitor with Ki of 1/2.1/0.8 pM for Pim1/2/3, respectively.

LGD-2226 (LGD2226) is an orally active, selective androgen receptor modulator (SARM) with binding Ki of 1 nM, >1000-fold selectivity over GR,PR, MR and ER.

Ligandrol (LGD-4033) is a novel nonsteroidal, oral SARM that binds to androgen receptor with high affinity (Ki of 1 nM) and selectivity.

LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research.

L-g-glutamyl-p-nitroanilide hydrochloride is a potent, competitive inhibitor of the neutral amino acid transporter ASCT2 (SLC1A5) with pKa of 13.79.

LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM.

L-Glutamic acid monosodium salt is the sodium salt of glutamic acid, found naturally in tomatoes, cheese and other foods.

LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.

LH 21 is a 1,2,4-triazole that acts as a cannabimimetic.

LH846 is a selective inhibitor of CK1δ (IC50 values are 290 nM, 1.3 uM and 2.5 uM for CK1δ, ε and α); displays no inhibitory activity at CK2.

L-Hexanoylcarnitine is an acylcarnitine and is found to be associated with celiac disease.

LHF-535 (LHF535, LHF 535) is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein, exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses with IC50 of 0.1-0.3 nM.

L-Homocysteine thiolactone hydrochloride is an intramolecular thioester of homocysteine; prevents translational incorporation of homocysteine into proteins.

Licofelone is a dual COX/LOX inhibitor being considered as a treatment for osteoarthritis.

Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent.

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.

Lifirafenib (BGB-283) potently inhibits RAF family kinases and EGFR activities in biochemical assays with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.

Lifirafenib（BGB-283） is a Novel potent and selective RAF Kinase and EGFR inhibitor.

Lifitegrast sodium, also known as SAR-1118, is an LFA-1 antagonist intended for the treatment of vascular complications of the eye.

Ligustilide possesses neuroprotective, vasorelaxation, antinociceptive and anti-inflammatory activities, it blocked the activation of MAPKs/IKK and the downstream transcription factors AP-1 and NF-κB.

LIMK1 and 2 dual inhibitor is a potent, selective LIMK1/2 inhibitor with IC50 of <10 nM for both, 15-fold selectivity over B-Raf (IC50=10-100 nM).

LIN28 inhibitor LI71 is a potent, cell-permeable inhibitor of LIN28 that abolishes LIN28-mediated oligouridylation with IC50 of 7 uM, binds the cold shock domain to suppress LIN28's activity against let-7 in leukemia cells and embryonic stem cells. .

Lin28-IN-1 is a small-molecule inhibitor of the Lin28/let-7 interaction with IC50 of 4.03 uM.

Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.

Lincomycin HCl (Lincocin)

Linderane is a mechanism-based inactivator of CYP2C9.

Linezolid (Zyvox) is a synthetic antibiotic used for the treatment of serious infections.

Linomide is an Immunomodulator; anti-angiogenic.

Linopirdine (DUP-996) is a potent Kv7 (KCNQ) voltage-gated potassium channels blcoker.

Linopirdine (DUP-996.

Liothyronine sodium (T3 Sodium sal) is the most potent form of thyroid hormone used to treat hypothyroidism and myxedema coma.

Lipofermata (CB16.2 aka) is a specific fatty acid transport (FATP) inhibitor, blocks human FATP2-mediated fatty acid uptake (IC50=4.84 uM in Caco-2 cells) without impacting other cellular functions.

Liproxstatin-1 analog is an analog of the ferroptosis inhibitor liproxstatin-1

Liproxstatin-1 is able to suppress ferroptosis in cells, in Gpx4(-/-) mice, and in a pre-clinical model of ischaemia/reperfusion-induced hepatic damage.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

Lirimilast (BAY 19-8004.

Lisinopril Dihydrate is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.

LIT-001 (LIT001) is the first nonpeptide Oxytocin receptor (OT-R) agonist with EC50 of 55 nM, Emax=96%.

LIT-001 trifluoroacetate (LIT001) is the first nonpeptide Oxytocin receptor (OT-R) agonist with EC50 of 55 nM, Emax=96%.

Litronesib is a selective, allosteric inhibitor of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing.

Lixivaptan is a highly potent, non-peptide, oral capsule that works by reducing the action of a hormone (vasopressin) that blocks fluid excretion.

LJ 001 ((LJ-001, LJ001) is a broad-spectrum antiviral agent targeting entry of enveloped viruses, including influenza A, filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, and HIV-1; specifically intercalates into viral membranes, irreversibly inactivates virions while leaving functionally intact envelope proteins, and inhibits viral entry at a step after virus binding but before virus-cell fusion; specifically inhibits virus-cell but not cell-cell fusion

LJH685 is a selective and potent RSK inhibitor.

LJI308 is a selective and potent RSK inhibitor.

L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.

LKY-047 is a decursin derivative that potently and selectively inhibits CYP2J2, competitively inhibits CYP2J2-mediated astemizole O-demethylase and terfenadine hydroxylase activity with Ki of 0.96 and 2.61 uM, respectively.

LLL3 is a structural analogue of STA-21 that acts as a novel STAT3 inhibitor, inhibits STAT3-dependent transcriptional and DNA binding activities.

LLP2A is a high-affinity, selective peptidomimetic ligand of α4β1 integrin with IC50 of 2 pM.

LLS2 is a novel potent Galectin-1 (Gal1) inhibitor that decreases membrane-associated H-Ras and K-Ras and contributed to the suppression of pErk pathway.

LLS30 is a potent, allosteric Galectin-1 (Gal-1) inhibitor, inhibits AR negative cells PC3, DU145, and AR positive cells, 22RV1 and CWR-R1 cells with IC50 of 10.4 μM, 5.3 μM, 3.3 μM and 5.9 μM, respectively.

LLY-2707 (LLY 2707, LLY2707) is a novel potent, selective, nonsteroidal glucocorticoid receptor antagonist with Ki of 2.13 nM.

LLY-283 (LLY283) is a potent, selective inhibitor of arginine methyltransferase 5 (PRMT5) with IC50 of 22 nM.

LLY-507 is a chemical probe for SMYD2 (a protein lysine methyltransferase).

LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.

LMD-009 (LMD 009, LMD009) is a potent, selective, nonpeptide CCR8 agonist that stimulates CCR8-mediated chemotaxis, inositol phosphate accumulation and calcium release with EC50 of 11-87 nM.

LMD-A (CCR8 antagonist LMD-A) is a highly potent, small molecule antagonist of chemokine receptor CCR8 with EC50 of 2.5 nM.

LMI070 (NVS-SM1) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.

LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor (IC50 values are 4.22, 11.9, 55.7, 320, 852, 881, and 1278 nM for HDAC 5, 4, 6, 1, 11, 2, and 8, respectively).

LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 has the potential for excessive sleep disorders[1].

LMP744(Mj-III-65,NSC-706744) is a DNA intercalator and topoisomerase inhibitor with antitumor activity.

LMPTP inhibitor 1 is a potent molecule for diabetes which can increase liver IR phosphorylation in vivo and reverses high-fat diet-induced diabetes by inhibiting the IR phosphatase LMPTP.

LMT-28 (LMT28) is a specific blocker of IL-6 signaling via inhibits IL-6Rβ (gp130) with IC50 of 5.9 uM (IL-6–induced luciferase activity), selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130.

LN-1-255 is a 6-alkylidene-2'-substituted penicillin sulfone that acts as an effective beta-lactamase inhibitor.

L-NAME is a nonselective inhibitor of nitric oxide synthetases (NOS) for nNOS (bovine), eNOS (human), and iNOS (murine), with Ki of 15 nM, 39 nM and 4.4 μM, respectively.

LOC-14 is a small molecule reversible Protein disulfide isomerase (PDI) inhibitor with Kd of 62 nM.

Lodoxamide is an antiallergic compound acting as a mast-cell stabilizer for the treatment of asthma and allergic conjunctivitis.

Loflucarban is an antiinfective drug

Loganetin is a non-toxic natural product that may be applied in the antibacterial drug development for treating multidrug-resistant Gram negative infections.

LOM612 is a potent activator of FOXO nuclear translocation, with an EC50 value of 1.5 μM in cells.

Lomefloxacin HCl (Maxaquin)

Lomeguatrib (PaTrin-2) is a modified guanine base, which can repress the activity of DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (MGMT) with an IC50 value of 6 nM.

Lomerizine dihydrochloride is a relatively new L- and T-type calcium channel blocker used in the treatment of migraine.

Lometrexol is a tight-binding antifolate inhibitor of the purine de novo enzyme glycinamide ribonucleotide formyltransferase (GARFT), was the first GARFT inhibitor to be investigated clinically.

Lomitapide (AEGR-733) is a novel proprietary MTP-inhibitor.

Lomustine (CeeNU)

Lonafarnib(Sch66336) is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B and N-ras with IC50 of 1.9 nM, 5.2 nM and 2.8 nM, respectively.

Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis.

Loperamide HCl is an opioid-receptor agonist used as long-acting synthetic antidiarrheals.

Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM,showed potent activity against COVID-19(SARS-COV-2).

Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT)..

Loratadine(SCH-29851) is a selective inverse peripheral histamine H1-receptor agonist with an IC50 of >32 μM.

Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.

Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.

Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.

Lorediplon is a new GABAA modulator Drug for treatment of insomnia.

L-ornithine has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle.

Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver.

Losartan is a potent, non peptide antagonist of the angiotensin II receptor type 1. This receptor initiates a signal cascade that causes vasoconstriction. Antagonism of this receptor in turn causes vasodilation by blocking the signal from angiotensin II.

Losartan is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.

Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.

Loteprednol etabonate

Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent).

Loxiglumide is a Exogenous cholecystokinin (CCK-A) receptor antagonist, stimulates calorie intake and hunger feelings in humans.

LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.

LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases.

LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively.

Loxoprofen is a non-steroidal anti-inflammatory drug that is quickly converted to the trans-alcohol metabolite. It is similar to ibuprofen and naproxen, while also being a Cycloxygenase (COX) inhibitor.

LP-211 is a selective and blood−brain barrier penetrant 5-HT7 receptor agonist, with a Ki of 0.58 nM, with high selectivity over 5-HT1A receptor (Ki, 188 nM) and D2 receptor (Ki, 142 nM).

LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9.